RecruitingNCT06694363
New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome
Studying Activated PI3K-delta syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Principal Investigator
- Sven Kracker, PHDInstitut National de la Santé Et de la Recherche Médicale, France
- Intervention
- Blood samples(biological)
- Enrollment
- 14 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2025 – 2029
Study locations (7)
- Hôpital Haut Levêque - BORDEAUX, Bordeaux, France
- Hôpital Pellerin Enfants - BORDEAUX, Bordeaux, France
- Hôpital Jeanne de Flandres - LILLE, Lille, France
- Hôpital La Timone adulte - MARSEILLE, Marseille, France
- Hôpital Necker Enfants Malades - PARIS, Paris, France
- CHU IUCT Oncopole - TOULOUSE, Toulouse, France
- Hôpital des enfants - TOULOUSE, Toulouse, France
Collaborators
URC-CIC Paris Descartes Necker Cochin
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06694363 on ClinicalTrials.govOther trials for Activated PI3K-delta syndrome
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT05693129Pediatric Patients Aged 1 to 6 Years With APDSPharming Technologies B.V.
- ACTIVE NOT RECRUITINGPHASE3NCT05438407Pediatric Patients Aged 4 to 11 Years With APDSPharming Technologies B.V.
- RECRUITINGNCT06566872Collecting Recorded Videos of Colonoscopy and Gastroscopy Tests for the Evaluation of the (ME-APDS).Magentiq Eye LTD